Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a...

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Histone deacetylase 6 (HDAC6) is a key therapeutic target for neurodegenerative diseases.
• Previous HDAC6 inhibitors like SW-100 showed efficacy but had limitations.
• Developing improved HDAC6 inhibitors is crucial for treating these disorders.

Purpose of the Study:

• To discover and characterize a novel HDAC6 inhibitor, SW-101.
• To evaluate SW-101's potency, selectivity, metabolic stability, and druglike properties.
• To assess SW-101's therapeutic potential in a mouse model of Charcot-Marie-Tooth disease type 2A (CMT2A).

Main Methods:

• Synthesis and characterization of SW-101, a tetrahydroquinoline-capped phenylhydroxamate-based HDAC6 inhibitor.
• X-ray crystallography to determine the binding mode of SW-101 to HDAC6.
• Pharmacological evaluation in cellular and animal models, including a CMT2A mouse model with mutant MFN2.
• Assessment of motor function and neuropathic symptoms in the CMT2A mouse model.

Main Results:

• SW-101 demonstrated excellent potency and selectivity for HDAC6.
• SW-101 exhibited improved metabolic stability and druglike properties compared to SW-100.
• X-ray crystallography elucidated the molecular mechanism of HDAC6 inhibition by SW-101.
• SW-101 treatment increased acetylated α-tubulin levels in the sciatic nerve.
• SW-101 ameliorated motor dysfunction and neuropathic symptoms in the CMT2A mouse model.

Conclusions:

• SW-101 is a potent and selective HDAC6 inhibitor with enhanced pharmacological properties.
• SW-101 shows significant therapeutic potential for treating CMT2A and potentially other neurodegenerative disorders.
• Further development of SW-101 as a disease-modifying therapeutic is warranted.